--- /home/parlparse/parldata/cmpages/wrans/answers2002-07-17.html	2004-07-16 14:20:17.000000000 +0100
+++ /home/parlparse/parldata/tmp/patchtmp-answers2002-07-17-ubOI10.html	2008-07-13 23:09:42.000000000 +0100
@@ -4686,10 +4686,9 @@
 
 <a name="20717w18.html_para16">No votes were taken at this meeting.
 
-<a name="20717w18.html_sbhd5"><H4><center>EU Committees</center></H4>
+<a name="20717w18.html_sbhd5"><H4><center>EU Committees (Scottish Executive Representation) </center></H4>
 
 
-(Scottish Executive Representation)
 <P>
 <P>
 <a name="20717w18.html_wqn5"><B> Angus Robertson: </B> 
@@ -10793,10 +10792,9 @@
 
 <a name="20717w42.html_para0">Copaxone (glatiramer acetate) is available on the NHS under the 'risk-sharing scheme for disease modifying drugs for multiple sclerosis (MS) that came into operation on 6 May 2002.
 
-<a name="20717w42.html_sbhd7"><H4><center>Royal Bournemouth and</center></H4>
+<a name="20717w42.html_sbhd7"><H4><center>Royal Bournemouth and Poole Hospitals NHS Trust </center></H4>
 
 
-Poole Hospitals NHS Trust
 <P>
 <P>
 <a name="20717w42.html_wqn7"><B> Mr. Swayne: </B> 
